A study was conducted to determine the effect of integrating clinical, genetic, and artificial intelligence-enabled ECG risk signals in prediction of AF risk.

Please provide your email address to receive an email when new articles are posted on . The AMALFI trial evaluated a completely remote approach to atrial fibrillation screening. Remote screening with ...

MADRID — A simple home-based screening strategy that involved wearing an ECG patch for 14 days increased the diagnosis of atrial fibrillation (AF) and associated use of anticoagulants in patients at ...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the impact of a new decision by ...

(RTTNews) - Tempus AI, Inc (TEM), Wednesday announced that the company has received 510(k) clearance from the U.S. Food and Drug Administration for its Tempus ECF-AF, which utilizes AI to detect ...

MADRID, Spain—The use of a noninvasive ECG patch modestly increases the detection of atrial fibrillation (AF) and treatment with anticoagulant therapy among patients at moderate to high risk for ...

A mail-based atrial fibrillation (AF) screening programme with ECG-patch monitoring led to a modest long-term increase in AF diagnosis and anticoagulation exposure in older patients at ...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced it has received 510(k) clearance from the U.S. Food and Drug ...

Data presented at ACC.26 demonstrate a high prevalence of clinically actionable arrhythmias across CKM patient populations using the Zio® ...

Roughly one-third of patients who develop new-onset atrial fibrillation (AF) while hospitalized for noncardiac surgery or a medical illness will have recurrent AF within the year, according to the ...